Literature DB >> 33590390

Protein tyrosine phosphatases (PTPs) in diabetes: causes and therapeutic opportunities.

Chiranjeev Sharma1, Youllee Kim1, Dohee Ahn1, Sang J Chung2.   

Abstract

Protein tyrosine phosphatases (PTPs) have an emerging paradigm for the development of antidiabetic drugs. Herein, we provide a comprehensive overview of the relevance of PTPs to type 2 diabetes (T2D) and the therapeutic opportunities thereof, while critically evaluating the potential challenges for PTP inhibitors to be next generation antidiabetics. This review briefly discusses the structure and function of PTPs. An account of importance and relevance of PTPs in various human diseases is presented with special attention to diabetes. The PTPs relevant to T2D have been targeted by small molecule inhibitors such as natural products and synthetic compounds as well as antisense nucleic acids. This review will give better understanding of the important concepts helpful in outlining the strategies for the development of new therapeutic agents with promising antidiabetic activities.

Entities:  

Keywords:  Antidiabetic agents; Antisense; Natural product; PTP inhibitor; Type 2 diabetes

Year:  2021        PMID： 33590390     DOI： 10.1007/s12272-021-01315-9

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN： 0253-6269            Impact factor:   4.946


  53 in total

Review 1.  Structural and evolutionary relationships among protein tyrosine phosphatase domains.

Authors:  J N Andersen; O H Mortensen; G H Peters; P G Drake; L F Iversen; O H Olsen; P G Jansen; H S Andersen; N K Tonks; N P Møller
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

2.  SAR of non-hydrolysable analogs of pyridoxal 5'-phosphate against low molecular weight protein tyrosine phosphatase isoforms.

Authors:  Shirin R DeSouza; Maxwell C Olson; Samantha L Tinucci; Erica K Sinner; Rebecca S Flynn; Quinlen F Marshall; Henry V Jakubowski; Edward J McIntee
Journal:  Bioorg Med Chem Lett       Date:  2020-06-10       Impact factor: 2.823

3.  Metabolic Disease: Protein tyrosine phosphatase inhibitor reverses diabetes.

Authors:  Sarah Crunkhorn
Journal:  Nat Rev Drug Discov       Date:  2017-04-21       Impact factor: 84.694

4.  Altered glucose homeostasis in mice lacking the receptor protein tyrosine phosphatase sigma.

Authors:  Mélanie J Chagnon; Mounib Elchebly; Noriko Uetani; Luce Dombrowski; Alan Cheng; Robert A Mooney; André Marette; Michel L Tremblay
Journal:  Can J Physiol Pharmacol       Date:  2006-07       Impact factor: 2.273

5.  Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling.

Authors:  Charles Y Cho; Seung-Hoi Koo; Yan Wang; Scott Callaway; Susan Hedrick; Puiying A Mak; Anthony P Orth; Eric C Peters; Enrique Saez; Marc Montminy; Peter G Schultz; Sumit K Chanda
Journal:  Cell Metab       Date:  2006-05       Impact factor: 27.287

Review 6.  The extended human PTPome: a growing tyrosine phosphatase family.

Authors:  Andrés Alonso; Rafael Pulido
Journal:  FEBS J       Date:  2015-12-16       Impact factor: 5.542

7.  Improved glucose homeostasis in mice with muscle-specific deletion of protein-tyrosine phosphatase 1B.

Authors:  Mirela Delibegovic; Kendra K Bence; Nimesh Mody; Eun-Gyoung Hong; Hwi Jin Ko; Jason K Kim; Barbara B Kahn; Benjamin G Neel
Journal:  Mol Cell Biol       Date:  2007-08-27       Impact factor: 4.272

Review 8.  Protein tyrosine phosphatases in the human genome.

Authors:  Andres Alonso; Joanna Sasin; Nunzio Bottini; Ilan Friedberg; Iddo Friedberg; Andrei Osterman; Adam Godzik; Tony Hunter; Jack Dixon; Tomas Mustelin
Journal:  Cell       Date:  2004-06-11       Impact factor: 41.582

9.  Reduction of protein-tyrosine phosphatase-1B increases insulin signaling in FAO hepatoma cells.

Authors:  Jill E Clampit; Joseph L Meuth; Harriet T Smith; Regina M Reilly; Michael R Jirousek; James M Trevillyan; Cristina M Rondinone
Journal:  Biochem Biophys Res Commun       Date:  2003-01-10       Impact factor: 3.575

10.  Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030.

Authors:  Christian Bommer; Vera Sagalova; Esther Heesemann; Jennifer Manne-Goehler; Rifat Atun; Till Bärnighausen; Justine Davies; Sebastian Vollmer
Journal:  Diabetes Care       Date:  2018-02-23       Impact factor: 19.112
View more
  4 in total

1.  Ethyl Gallate Dual-Targeting PTPN6 and PPARγ Shows Anti-Diabetic and Anti-Obese Effects.

Authors:  Dohee Ahn; Jinsoo Kim; Gibeom Nam; Xiaodi Zhao; Jihee Kwon; Ji Young Hwang; Jae Kwan Kim; Sun-Young Yoon; Sang J Chung
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

2.  Structure-Activity Relationship of Synthetic Ginkgolic Acid Analogs for Treating Type 2 Diabetes by PTPN9 Inhibition.

Authors:  Jinsoo Kim; Jinyoung Son; Dohee Ahn; Gibeom Nam; Xiaodi Zhao; Hyuna Park; Woojoo Jeong; Sang J Chung
Journal:  Int J Mol Sci       Date:  2022-04-01       Impact factor: 5.923

3.  Terminalin from African Mango (Irvingia gabonensis) Stimulates Glucose Uptake through Inhibition of Protein Tyrosine Phosphatases.

Authors:  Sun-Young Yoon; Jinsoo Kim; Bum Soo Lee; Su Cheol Baek; Sang J Chung; Ki Hyun Kim
Journal:  Biomolecules       Date:  2022-02-17

4.  Computation Screening of Multi-Target Antidiabetic Properties of Phytochemicals in Common Edible Mediterranean Plants.

Authors:  Vlasios Goulas; Antonio J Banegas-Luna; Athena Constantinou; Horacio Pérez-Sánchez; Alexandra Barbouti
Journal:  Plants (Basel)       Date:  2022-06-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.